If we are going to defeat HIV, we cannot abandon our commitment to fully fund research, and we cannot walk away from our work ...

Gilead Sciences’ long-acting drug to block HIV has the potential to end the AIDS epidemic worldwide. But accessibility ...

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review ...

That shows how the company is now overvalued in our view. The largest risk to our thesis is if Gilead Sciences can achieve ...

Best Pharma Stocks to Invest in Now. In this article, we are going to take a look at where Gilead Sciences, Inc.

Congresswoman Marjorie Taylor Greene has made a name for herself in the stock market by having a knack for timing ...

As the Trump administration slashes funding for HIV-related research and infrastructure, Gilead, Immunocore and more are targeting the next goalpost: a cure.

The HIV Clinical Trials Market focuses on the systematic evaluation of novel antiretroviral therapies, combination regimens, long-acting injectables, and immunotherapeutic approaches to control and ...

Metformin use in patients with HIV and type 2 diabetes who had at least 2 years of exposure to effective ART showed no significant effect on immune reconstitution.

President Trump has eliminated funding for programs aimed at ending the growing HIV epidemic among minority communities, ...

We recently published a list of 15 Best Stocks to Buy According to Jim Simons’ Renaissance Technologies In this article, we ...